- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02833064
Biomarkers in Liver Failure
Identification of Outcome Biomarkers in Patients With Liver Failure.
Study Overview
Status
Intervention / Treatment
Detailed Description
For inpatients, the investigators wish to collect biological samples from each patient once daily for the first seven days of their admission. 25mls of blood will be taken daily for research purposes, at the same time at routine clinical samples to reduce discomfort from additional venepuncture. One urine sample will be taken daily (which can be taken from a catheter if the patient has a catheter in place), and a sample of stool if the patient moves their bowels. The investigators wish to collect breath for analysis, at one point during the first seven days of admission. Breath analysis requires the patients to be fasted for four hours (with the exception of water) prior to the test. If the patient undergoes liver transplantation during their admission, a small sample of explanted liver tissue will be obtained for later analysis.
For outpatients (acute liver injury, stable cirrhotics, non-cirrhotic liver disease), the investigators will ask them to attend the ward or the outpatient department for collection of biological samples. The investigators will take 25 mls of blood as above, along with a urine and stool sample if they are able to provide this at their first attendance. Breath analysis will also be undertaken during this visit to the hospital, after a 4 hour fast (with the exception of water). Outpatients will then be asked to return one month later, when further blood (25mls), urine and stool samples will be collected.
As a pilot study, the investigators wish to perform MRI scanning on a subset of 10 patients with paracetamol induced acute liver failure. Paracetamol induced acute liver failure is associated with a particularly rapid course, characterised by hepatic encephalopathy and renal impairment. In view of the potential for renal impairment, intravenous contrast will not be used for these scans, but alternative techniques employed such as artertial spin labelling.
The participant does not need to consent to each individual part of the study to be able to take part.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Kenneth Simpson, MD, PhD
- Phone Number: 0044 131 242 1621
- Email: k.simpson@ed.ac.uk
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
- Acute liver failure
- Acute liver injury
- Acute on chronic hepatic failure
- Stable cirrhotics
- Non-cirrhotic liver disease
Description
Inclusion Criteria:
- acute liver injury (newly deranged liver function tests (LFTs) and coagulopathy with International Normalized Ratio (INR) >1.5 in absence of chronic liver disease)
- acute liver failure ( as above, plus hepatic encephalopathy)
- acute on chronic liver failure (worsening of LFTS and development of at least 1 organ failure in patient with cirrhosis)
- stable cirrhosis
- non-cirrhotic liver disease
Exclusion Criteria:
- refusal of consent
- withdrawal of consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Acute Liver Failure
|
Blood, urine, stool and breath sampling and analysis
|
Acute Liver Injury
- biological sampling
|
Blood, urine, stool and breath sampling and analysis
|
Acute on Chronic Hepatic Injury
- biological sampling
|
Blood, urine, stool and breath sampling and analysis
|
Stable Cirrhotics
- biological sampling
|
Blood, urine, stool and breath sampling and analysis
|
Non-cirrhotic liver disease
- biological sampling
|
Blood, urine, stool and breath sampling and analysis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Identification of biomarkers and radiological markers predictive of development of complications and outcomes in acute liver injury and acute liver failure.
Time Frame: 10 years
|
10 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Identification of proteins involved in the pathogenesis of acute liver injury and acute liver failure
Time Frame: 10 years
|
10 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AC16086
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute on Chronic Hepatic Failure
-
Pere GinesClinica Universidad de Navarra, Universidad de NavarraTerminatedAllogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure (Liveradvance)Acute on Chronic Hepatic FailureSpain
-
Chulalongkorn UniversityRecruitingAcute-On-Chronic Liver Failure | Acute on Chronic Hepatic FailureThailand
-
Hexaell Biotech Co., Ltd.RecruitingLiver Failure | Hepatitis | Acute on Chronic Hepatic FailureChina
-
Hepa Wash GmbHTerminatedAcute on Chronic Hepatic FailureGermany
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute on Chronic Hepatic FailureIndia
-
Third Affiliated Hospital, Sun Yat-Sen UniversityWithdrawnLiver Failure, Acute on ChronicChina
-
Tianjin Weikai Bioeng., Ltd.Tianjin Nankai HospitalUnknownLiver Failure, Acute on ChronicChina
-
Medical University of GrazFresenius Medical Care North AmericaCompleted
-
Aga Khan UniversityNational Institute of Liver & GI Diseases, PakistanNot yet recruiting
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompletedLiver Failure, Acute | Liver Failure, Acute on ChronicItaly
Clinical Trials on Non-contrast magnetic resonance imaging
-
Mario Negri Institute for Pharmacological ResearchEC-DG ResearchCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingOsteoradionecrosis | Malignant Skull Base Neoplasm | Malignant Oral Cavity NeoplasmUnited States
-
Bristol-Myers SquibbPfizerCompletedThrombosisArgentina, United States, Germany, Mexico, Canada, Netherlands, Brazil, Austria, United Kingdom
-
Insel Gruppe AG, University Hospital BernRecruiting
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Children's Hospital Medical Center, CincinnatiTerminated
-
University of MiamiRecruitingIntracranial Hypertension | Intracranial PathologyUnited States
-
Assiut UniversityUnknown
-
Mario Negri Institute for Pharmacological ResearchAlexion PharmaceuticalsCompletedIC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative GlomerulonephritisItaly
-
Vanderbilt University Medical CenterUniversity of Colorado, Denver; Juvenile Diabetes Research Foundation; University... and other collaboratorsEnrolling by invitationDiabetes MellitusUnited States, Australia